GenSpera gets Grebow on board
This article was originally published in Scrip
GenSpera, a development-stage oncology company, has appointed Dr Peter Grebow to its board of directors. Dr Grebow has 37 years' experience in the pharmaceutical industry having served at Cephalon from 1991-2011, most recently as executive vice-president of technical operations. He is now president of P.E. Grebow Consulting, which he founded in 2011, and a director of both Optimer Pharmaceuticals and Q Holdings.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.